EVAX — EVAXION BIOTECH A/S
As of Q2 2026, 3 SEC-registered investment managers reported holding EVAX (EVAXION BIOTECH A/S) in their latest 13F filings, with a combined reported value of $237.64K across 76.66K shares. That is +34.5% by share count (+19.66K shares) versus the previous quarter, while reported value moved +12.1%. Ownership is concentrated: the five largest holders account for 100.0% of reported value and the top ten for 100.0%.
Compared with the prior quarter, 1 opened new positions, 1 added to existing stakes, 1 trimmed. 13F holdings are quarter-end snapshots, so these moves reflect positioning as of Q2 2026, not real-time trading.
EVAX is classified in the Health Care sector.
All figures on this page are computed from SEC Form 13F quarterly filings. 13F filers disclose long positions of $100,000 or more within 45 days of quarter end; short positions, options overlays and intra-quarter trades are not included, so treat the numbers as a quarterly snapshot of institutional ownership rather than real-time positioning.
| Fund | Quarter | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|---|
| Point72 Asset Management history | Q4 2025 | 33.10K | $157.89K | 0.00% | New |
| Citadel Advisors history | Q2 2026 | 36.58K | $113.41K | 0.00% | Add |
| Renaissance Technologies history | Q2 2026 | 33.80K | $104.78K | 0.00% | Reduce |
| Two Sigma Investments history | Q1 2022 | 20.59K | $62.00K | 0.00% | Reduce |
| UBS Group AG history | Q2 2026 | 6.28K | $19.45K | 0.00% | New |
| Millennium Management history | Q4 2024 | 22.54K | $18.77K | 0.00% | New |
| Citigroup Inc history | Q2 2022 | 2.94K | $6.00K | 0.00% | Reduce |
| BlackRock Inc history | Q3 2024 | 1.51K | $4.70K | 0.00% | New |
| Morgan Stanley history | Q3 2023 | 3.45K | $2.87K | 0.00% | Hold |
| JPMorgan Chase & Co history | Q4 2024 | 780 | $650 | 0.00% | Hold |
New Positions (Q2 2026)
- UBS Group AG 6.28K sh · $19.45K
Fully Exited (vs previous quarter)
No tracked fund fully exited this quarter.
Fund Position History — shares by quarter (top 10 funds)
| Fund | Q3 2021 | Q4 2021 | Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Citadel Advisors | — | 154.50K | 256.65K | 453.99K | 565.01K | 14.98K | 19.50K | — | — | 68.73K | 13.89K | — | 14.82K | — | — | — | — | — | 17.77K | 36.58K |
| Renaissance Technologies | — | 20.27K | — | 11.60K | — | — | — | — | — | 14.00K | — | — | — | — | — | — | — | — | 39.23K | 33.80K |
| UBS Group AG | 2.26K | 3.52K | 1.96K | 1.10K | 2.65K | 5.08K | 6.58K | 222 | 4.00K | 277 | — | — | — | — | 6.52K | 2.04K | 1 | 3.22K | — | 6.28K |
| Point72 Asset Management | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 33.10K | — | — |
| BlackRock Inc | — | — | — | — | — | — | — | — | — | — | — | — | 1.51K | — | — | — | — | — | — | — |
| Morgan Stanley | 200 | 3.70K | 8.36K | 4.30K | 3.70K | 3.70K | 36.23K | 3.45K | 3.45K | — | — | — | — | — | — | — | — | — | — | — |
| JPMorgan Chase & Co | — | — | — | — | — | — | — | 29.15K | 9.28K | 9.00K | 705 | 2.18K | 780 | 780 | — | — | — | — | — | — |
| Two Sigma Investments | — | 40.92K | 20.59K | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Citigroup Inc | — | — | 3.19K | 2.94K | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Millennium Management | — | — | — | — | — | — | 29.14K | — | — | — | — | — | — | 22.54K | — | — | — | — | — | — |
▲ Bought Low (fund opened/added, stock rose ≥5% next quarter) ▼ Sold High (fund reduced, stock fell ≥5% next quarter)
Drag / scroll to zoom · Default shows the most recent year · Annotations come from quarterly fund actions in 13F filings · Hover a marker for details